Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pegylated zinc(II) phthalocyanine 1b (ZnPc 1b) is a research-stage small molecule photosensitizer designed for use in photodynamic therapy (PDT). It consists of a zinc(II) phthalocyanine core substituted with polyethylene glycol (PEG) chains to improve water solubility and biocompatibility. Upon irradiation with specific wavelengths of light, the molecule generates reactive oxygen species (ROS), primarily singlet oxygen, which induces cytotoxicity in targeted cancer cells. In vitro studies have demonstrated its phototoxic effects against various cancer cell lines, including colorectal adenocarcinoma (HT29), hepatocarcinoma (HepG2), and head and neck cancer (A253, FaDu). It is currently utilized as a laboratory tool in academic research and as a precursor for more complex functionalized derivatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pegylated zinc(ii) phthalocyanine 1b.